Trials in Progress
ARASEC: Open-label Study of Androgen Receptor Inhibition With dArolutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Men With Metastatic Hormone-Sensitive Prostate Cancer Using an External Control Arm
Transformative Clinical Trials
Videos
Open-label Study of Androgen Receptor Inhibition With dArolutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Men With Metastatic Hormone-Sensitive Prostate Cancer Using an External Control Arm
- Condition: Metastatic Hormone-sensitive Prostate Cancer
- Study ID: NCT05059236
Physician-Scientist Review Articles
State of the Evidence Review Articles
Conference Coverage
Conference Highlights Written by Physician-Scientist